OBJECTIVE:Glutamine is an important fuel for rapidly dividing cells such as enterocytes and lymphocytes. Exogenous glutamine supplementation in catabolic states preserves intestinal mucosal structure and function, decreases bacterial translocation, and supports normal immunologic responses. This study was planned to assess the effect of glutamine supplementation on duration and severity of diarrhea and to assess its immunomodulatory effect by measuring serum interleukin-8 (IL-8) and salivary immunoglobulin A (sIgA) in children with acute diarrhea. METHODS: In this placebo-controlled, double-blind and randomized trial, 6- to 24-month-old otherwise healthy children admitted to the Diarrheal Diseases Training and Treatment Center with acute diarrhea received either 0.3 g/kg/day ofglutamine (n = 63) orplacebo (n = 65) for 7 days. Serum IL-8and sIgA levels were determined on admission and 7 days later. All cases were followed until the diarrheal episode ended. Anthropometric measurements and history of subsequent infectious diseases were monitored monthly for 3 months after treatment. RESULTS:Mean duration of diarrhea in the glutamine treated group was significantly shorter than that of the placebo group (3.40 +/- 1.96 days, 4.57 +/- 2.48 days, respectively; P = 0.004). No differences in serum IL-8 and sIgA were found between groups on admission or 1 week later. During 3 month follow-up, mean weight gain and incidence of infectious diseases were similar in both groups. CONCLUSION:Duration of diarrhea was shorter in children supplemented with glutamine. The beneficial impact of glutamine supplementation seems to be through effects on gastrointestinal mucosa rather than the host immune response.
RCT Entities:
OBJECTIVE:Glutamine is an important fuel for rapidly dividing cells such as enterocytes and lymphocytes. Exogenous glutamine supplementation in catabolic states preserves intestinal mucosal structure and function, decreases bacterial translocation, and supports normal immunologic responses. This study was planned to assess the effect of glutamine supplementation on duration and severity of diarrhea and to assess its immunomodulatory effect by measuring serum interleukin-8 (IL-8) and salivary immunoglobulin A (sIgA) in children with acute diarrhea. METHODS: In this placebo-controlled, double-blind and randomized trial, 6- to 24-month-old otherwise healthy children admitted to the Diarrheal Diseases Training and Treatment Center with acute diarrhea received either 0.3 g/kg/day of glutamine (n = 63) or placebo (n = 65) for 7 days. Serum IL-8 and sIgA levels were determined on admission and 7 days later. All cases were followed until the diarrheal episode ended. Anthropometric measurements and history of subsequent infectious diseases were monitored monthly for 3 months after treatment. RESULTS: Mean duration of diarrhea in the glutamine treated group was significantly shorter than that of the placebo group (3.40 +/- 1.96 days, 4.57 +/- 2.48 days, respectively; P = 0.004). No differences in serum IL-8 and sIgA were found between groups on admission or 1 week later. During 3 month follow-up, mean weight gain and incidence of infectious diseases were similar in both groups. CONCLUSION: Duration of diarrhea was shorter in children supplemented with glutamine. The beneficial impact of glutamine supplementation seems to be through effects on gastrointestinal mucosa rather than the host immune response.
Authors: Patricia B Pavlinac; Rebecca L Brander; Hannah E Atlas; Grace C John-Stewart; Donna M Denno; Judd L Walson Journal: BMC Public Health Date: 2018-02-01 Impact factor: 3.295
Authors: Manuel B Braga-Neto; Bruna M C Oliveira; Raphael S Rodrigues; Francisco J Noronha; Renata F Leitao; Gerly A C Brito; Aldo A Lima; Richard L Guerrant; Cirle A Warren Journal: Cancer Biol Ther Date: 2012-09-17 Impact factor: 4.742
Authors: Manuel B Braga-Neto; Cirle A Warren; Reinaldo B Oriá; Manuel S Monteiro; Andressa A S Maciel; Gerly A C Brito; Aldo A M Lima; Richard L Guerrant Journal: Dig Dis Sci Date: 2008-03-06 Impact factor: 3.199
Authors: Joseph Carcillo; Richard Holubkov; J Michael Dean; John Berger; Kathleen L Meert; K J S Anand; Jerry Zimmerman; Christopher J L Newth; Rick Harrison; Douglas F Willson; Carol Nicholson Journal: JPEN J Parenter Enteral Nutr Date: 2009-04-14 Impact factor: 4.016
Authors: Joseph A Carcillo; J Michael Dean; Richard Holubkov; John Berger; Kathleen L Meert; K J S Anand; Jerry Zimmerman; Christopher J L Newth; Rick Harrison; Jeri Burr; Douglas F Willson; Carol Nicholson Journal: Pediatr Crit Care Med Date: 2012-03 Impact factor: 3.624
Authors: Douglas F Willson; J Michael Dean; Kathleen L Meert; Christopher J L Newth; Kanwaljeet J S Anand; John Berger; Rick Harrison; Jerry Zimmerman; Joseph Carcillo; Murray Pollack; Richard Holubkov; Tammara L Jenkins; Carol Nicholson Journal: Pediatr Crit Care Med Date: 2010-01 Impact factor: 3.624
Authors: Joseph A Carcillo; J Michael Dean; Richard Holubkov; John Berger; Kathleen L Meert; Kanwaljeet J S Anand; Jerry J Zimmerman; Christopher J L Newth; Rick Harrison; Jeri Burr; Douglas F Willson; Carol Nicholson; Michael J Bell; Robert A Berg; Thomas P Shanley; Sabrina M Heidemann; Heidi Dalton; Tammara L Jenkins; Allan Doctor; Angie Webster; Robert F Tamburro Journal: JPEN J Parenter Enteral Nutr Date: 2016-09-22 Impact factor: 4.016